Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision identifier changed from v3.8.0 to v3.8.1, reflecting a site update rather than a change to the clinical trial record.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check29 days agoChange DetectedA site-wide NIH notice about replacing the term “Artificial Intelligence” with “Super Intelligence” during a terminology transition appears above the study record.SummaryDifference0.8%

- Check36 days agoChange DetectedThe site footer’s revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check43 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check64 days agoChange DetectedA new revision entry v3.7.0 was added to the study's history, and the previous revision v3.6.6 was removed.SummaryDifference0.1%

Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.